Prime Medicine (PRME) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$0.32.
- Prime Medicine's EPS (Weighted Average and Diluted) rose 27.27% to -$0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 30.10%. This contributed to the annual value of -$1.65 for FY2024, which is 24.31% up from last year.
- Latest data reveals that Prime Medicine reported EPS (Weighted Average and Diluted) of -$0.32 as of Q3 2025, which was up 21.95% from -$0.41 recorded in Q2 2025.
- Prime Medicine's EPS (Weighted Average and Diluted)'s 5-year high stood at $0.72 during Q4 2022, with a 5-year trough of -$4.45 in Q4 2021.
- Over the past 3 years, Prime Medicine's median EPS (Weighted Average and Diluted) value was -$0.44 (recorded in 2024), while the average stood at -$0.45.
- Per our database at Business Quant, Prime Medicine's EPS (Weighted Average and Diluted) skyrocketed by 116.18% in 2022 and then plummeted by 200.00% in 2023.
- Quarterly analysis of 5 years shows Prime Medicine's EPS (Weighted Average and Diluted) stood at -$4.45 in 2021, then soared by 116.18% to $0.72 in 2022, then plummeted by 200.00% to -$0.72 in 2023, then soared by 56.94% to -$0.31 in 2024, then rose by 27.27% to -$0.32 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.32 in Q3 2025, compared to -$0.41 in Q2 2025 and -$0.40 in Q1 2025.